Abeome Corporation is a biotechnology startup founded in 2000 that has developed a groundbreaking technology called DiSH. This technology enables efficient screening for new targets by using fluorescent-labeled antigens to bind surface-expressed antibodies, making the isolation and cloning of desired cells significantly easier. The company is actively seeking partners interested in leveraging its DiSH technology to accelerate pre-clinical identification and screening of monoclonal antibody targets. Abeome's strategic approach includes licensing the platform technology to leading pharmaceutical/biotech companies, offering fee-for-service antibody generation, and co-developing its own monoclonal antibodies for therapeutic and diagnostic applications. Notably, the company offers non-exclusive licenses for unlimited access and commercialization of the technology or by specific fields of interest, such as research use, diagnostics, and animal health. The last investment in Abeome Corporation was a Seed Round investment made by ATDC on March 12, 2008.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
12 Mar 2008 |
| Seed Round | Unknown | 1 |
|
21 Jun 2007 |
No recent news or press coverage available for Abeome Corporation.
We care about your data, and we'd love to use cookies make your experience better.
